UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 223

of 'Chemotherapy hepatotoxicity and dose modification in patients with liver disease'

223
TI
Fulminant hepatic failure secondary to erlotinib.
AU
Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD
SO
Clin Gastroenterol Hepatol. 2007;5(8):917. Epub 2007 Jul 10.
 
Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.
AD
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. wliu3@bics.bwh.harvard.edu
PMID